Lowering blood glucose during hip surgery does not influence coagulation activation

Area of Science:

• Endocrinology
• Metabolic Disorders
• Surgical Outcomes

Background:

• Hyperglycemia post-hip surgery correlates with increased coagulation and venous thromboembolism (VTE) risk.
• The effect of glucose-lowering interventions on coagulation activation during hip surgery remains unclear.

Purpose of the Study:

• To evaluate the efficacy of liraglutide, a GLP-1 analogue, in reducing glucose levels during and after hip surgery.
• To investigate the influence of liraglutide on coagulation activation in this patient cohort.

Main Methods:

• A randomized trial involving 37 obese patients undergoing hip surgery.
• Participants received either subcutaneous liraglutide or placebo for four days, starting pre-operatively.
• Glucose levels and coagulation indices were measured at pre-operative, 2-hour post-operative, and 3-day post-operative time points.

Main Results:

• Liraglutide significantly reduced glucose levels by day three post-surgery (5.5 vs. 5.8 mmol/L, P=0.04).
• No significant differences in most coagulation indices were observed between groups.
• D-dimer levels were lower, and Factor VIII (FVIII) levels were higher in the liraglutide group at specific post-operative time points.

Conclusions:

• Liraglutide demonstrated a moderate glucose-lowering effect in non-diabetic/prediabetic obese patients undergoing hip surgery.
• The study found no significant impact of liraglutide on overall coagulation activation markers.
• Findings suggest liraglutide may not substantially mitigate the risk of VTE associated with post-operative hyperglycemia in this setting.